Skip to main content
. Author manuscript; available in PMC: 2022 Oct 26.
Published in final edited form as: Eur Urol Oncol. 2020 Dec 4;4(3):370–395. doi: 10.1016/j.euo.2020.11.002

Table 4.

Key findings of the systematic review and recommendations for future research purpose

Indication Key findings Recommended research
Overall - heterogeneous study designs, definitions of outcome variables and imaging techniques

- most studies were limited by insufficient sample size and low event rate with accordingly high level of uncertainty
- RCTs with adequate study sample and event rates

- direct comparison between mpMRI and PET/CT with:

   - standardized reporting (PIRADS, ESUR), clear definitions and same techniques

   - blinding to clinical and pathological data

   - central pathological and radiological review

   - determination of different anatomical LN regions for LNI

- external validation of models incorporating imaging results into existing tools

- RCTs comparing different imaging modalities
EPE + SVI - most studies reported on MRI

- standardized reporting play an important role

- reader experience and academic setting might improve performance

- possible beneficial effect by adding imaging data to existing risk tools but no external validations so far
LNI - PET seems more promising than MRI

- size of lymph node metastases most important for detection among all modalities
M - one RCT demonstrating superiority of PSMA-PET/CT to conventional staging, but:

   - no blinding

   - no comparisons between different imaging modalities

- WB-MRI, NaF-PET/CT, FCH-PET/CT of unknown clinical utility
- first: RCTs evaluating role of WB-MRI, NaF- and FCH-PET/CT compared to conventional imaging

- second: RCTs comparing different imaging modalities

   - blinding of radiologists and physicians to clinical data

   - central pathological and radiological review

Abbreviations:

EPE extraprostatic extension

SVI seminal vesicle invasion

LNI lymph node invasion

M distant metastases

RCT randomized controlled trial

PET/CT positron emission tomography/computed tomography

PSMA prostate specific membrane antigen

NaF 18F-Sodiumfluoride

FCH 18F-Fluorocholine

mp/WB-MRI multiparametric/whole body magnetic resonance imaging